Stock Fundamentals

Company Information

Company Name
Castle Biosciences Inc
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NASDAQ
ISIN: US14843C1053
CIK: 0000908605
CUSIP: 14843C105
Currency: USD
Full Time Employees: 942
Phone: 866 788 9007
Fiscal Year End: December
IPO Date: Jul 25, 2019
Description:

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Address:

1500 W. Parkwood Ave, Friendswood, TX, United States, 77546

Directors & Officers

Name Title Year Born
Mr. Derek J. Maetzold Founder, CEO, President & Director 1962
Mr. Frank Stokes CFO & Treasurer 1970
Ms. Kristen M. Oelschlager R.N. Chief Operating Officer 1969
Mr. Tobin W. Juvenal Chief Commercial Officer 1961
Ms. Camilla Zuckero Vice President of Investor Relations & Corporate Affairs NA
Mr. Kevin Doman Vice President of Sales NA
Dr. Jay Braxton Pharm.D. VP of Marketing & Brand Manager of Uveal Melanoma (UM) NA
Ms. Keli Greenberg Vice President of Human Resources NA
Dr. Matthew Goldberg M.D. Senior Vice President of Medical NA
Ms. Trisha Poteet Senior VP of Clinical Services & Manufacturing Operations NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 21, 2026 Derek J Maetzold N/A Sale 3.62K $25.10 $90.91K
Apr 21, 2026 Derek J Maetzold N/A Sale 550.00 $25.10 $13.81K
Apr 06, 2026 Derek J Maetzold N/A Sale 6.21K $25.03 $155.54K
Apr 06, 2026 Derek J Maetzold N/A Sale 3.62K $25.03 $90.66K
Mar 18, 2026 Derek J Maetzold N/A Sale 650.00 $25.39 $16.50K
Mar 17, 2026 Derek J Maetzold N/A Sale 18.65K $25.93 $483.59K
Mar 12, 2026 Tobin W Juvenal N/A Sale 20.86K $25.24 $526.58K
Mar 05, 2026 Frank Stokes N/A Sale 6.00K $27.98 $167.91K
Mar 05, 2026 G Bradley Cole N/A Sale 7.40K $28.47 $210.76K
Mar 03, 2026 Frank Stokes N/A Sale 7.00K $27.44 $192.08K
Feb 04, 2026 Derek J Maetzold N/A Sale 817.00 $37.99 $31.04K
Feb 03, 2026 Derek J Maetzold N/A Sale 3.20K $39.91 $127.71K
Jan 20, 2026 Derek J Maetzold N/A Sale 4.02K $40.01 $160.72K
Jan 06, 2026 Derek J Maetzold N/A Sale 1.34K $40.10 $53.69K
Jan 05, 2026 Derek J Maetzold N/A Sale 2.68K $38.09 $102.01K
Dec 22, 2025 Derek J Maetzold N/A Sale 830.00 $40.35 $33.49K
Dec 17, 2025 Derek J Maetzold N/A Sale 509.00 $40.04 $20.38K
Dec 17, 2025 Kristen M Oelschlager N/A Sale 14.89K $39.31 $585.25K
Dec 04, 2025 Derek J Maetzold N/A Sale 1.34K $40.03 $53.60K
Nov 25, 2025 Derek J Maetzold N/A Sale 5.12K $40.05 $204.86K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 2.98M Mar 31, 2026 9.84% $0.00 -3.94%
RTW INVESTMENTS, LLC 2.76M Mar 31, 2026 9.09% $0.67 30.40%
Vanguard Group Inc 2.20M Dec 31, 2025 7.25% $0.00 1.27%
Principal Financial Group Inc 1.77M Mar 31, 2026 5.84% $0.02 -2.09%
Portolan Capital Management, LLC 1.35M Mar 31, 2026 4.45% $1.76 -21.92%
Dimensional Fund Advisors, Inc. 1.04M Mar 31, 2026 3.43% $0.01 -9.10%
Summit Partners Public Asset Management, LLC 940.69K Mar 31, 2026 3.10% $0.62 -11.15%
Allianz Asset Management AG 811.32K Mar 31, 2026 2.68% $0.02 30.38%
State Street Corp 769.08K Mar 31, 2026 2.54% $0.00 4.43%
Geode Capital Management, LLC 728.10K Mar 31, 2026 2.40% $0.00 1.84%
AIGH Capital Management, LLC 590.60K Mar 31, 2026 1.95% $1.98 -5.46%
Qube Research & Technologies 559.58K Mar 31, 2026 1.85% $0.02 137.60%
Palisade Capital Management LLc 535.88K Mar 31, 2026 1.77% $0.44 -5.62%
Renaissance Technologies Corp 532.80K Mar 31, 2026 1.76% $0.02 8.05%
Nuveen, LLC 522.13K Mar 31, 2026 1.72% $0.00 -0.49%
Acadian Asset Management LLC 484.44K Mar 31, 2026 1.60% $0.02 19,371.10%
Wasatch Advisors LP 455.04K Mar 31, 2026 1.50% $0.07 -15.30%
Morgan Stanley - Brokerage Accounts 428.93K Mar 31, 2026 1.41% $0.00 110.70%
Eventide Asset Management, LLC 386.43K Mar 31, 2026 1.27% $0.16 26.70%
Connor Clark & Lunn Inv Mgmt Ltd 377.08K Mar 31, 2026 1.24% $0.02 -2.94%

Shares Statistics

Shares Outstanding: 30.33M
Shares Float: 26.76M
% Insiders: 272.80%
% Institutions: 9,300.10%
Short % Float: 4.78%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 823.96K 2.72% ▲ 0.00% Apr 30, 2026
2 Principal U.S. Small Cap Select Equity 753.64K 2.48% ▼ 9.68% Mar 31, 2026
3 Principal U.S. Small Cap Equity 753.64K 2.48% ▼ 9.68% Mar 31, 2026
4 Principal SmallCap R5 708.24K 2.34% ▼ 6.02% Apr 30, 2026
5 iShares Russell 2000 ETF 678.19K 2.24% ▲ 0.85% Apr 30, 2026
6 Strategic Advisers U.S. Total Stock 664.36K 2.19% ▲ 0.00% Mar 31, 2026
7 Palisade Small Cap Core Equity 384.34K 1.27% ▲ 1.37% Mar 31, 2026
8 Vanguard Institutional Extnd Mkt Idx Tr 329.46K 1.09% ▲ 1.14% Apr 30, 2026
9 Eventide Healthcare & Life Sciences I 305.00K 1.01% ▲ 0.00% Dec 31, 2025
10 Fidelity Small Cap Index 278.08K 0.92% ▲ 1.10% Feb 28, 2026

Valuation Metrics

Enterprise Value: $409.84M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $597.80M
EBITDA: $-18.35M
Book Value: $15.23
Earnings/Share: $-0.42
Profit Margin: -3.78%
Operating Margin: -22.00%
ROA (TTM): -3.97%
ROE (TTM): -2.85%
Revenue (TTM): $339.92M
Revenue/Share (TTM): $11.60
Earnings Growth (YOY): -51.60%
Revenue Growth (YOY): -4.90%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 5.26x 0.02x 0.19x -497.79x 1.00x
2024-12-31 7.29x 0.03x 0.14x 15.03x 0.31x
2023-12-31 6.20x 0.00x 0.14x -6,179.73x -0.03x
2022-12-31 8.09x 0.00x 0.11x -4,285.59x -0.03x
2021-12-31 14.21x 0.00x 0.11x -40,079.00x -0.03x
2020-12-31 20.58x 0.01x 0.05x -2.48x -0.82x
2019-12-31 7.63x 0.30x 0.29x 1.60x 2.44x
2018-12-31 2.69x -2.43x 1.45x -1.69x -6.51x
2017-12-31 1.28x -1.30x 2.45x -6.61x -1.79x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CSTL.US!